With this contracting file whose conditions are established in this document, it is intended to cover the needs in Osakidetza for the use of medicines included in the file for therapeutic indications approved by the competent health authority and which are summarized in the report's report.

Centralized contracting of the supply of intravenous Rituximab (DOE) medicine for all for all Osakidetza service organizations and privately owned and non-profit health centers, located in the Autonomous Community of Euskadi, within the framework provided for in article 30 of Law 8/1997, of June 26, on the Health Organization of Euskadi, which sign a linkage agreement with Osakidetza / Basque Health Service).

Single intravenous Rituximab (DOE) lot

Active substance: Rituximab (DOE)

Amount of active substance: according to presentation

Pharmaceutical form: vial

Packaging conditions: unit dose

Maximum unit price: EUR 1.05 / mg (taxes not included)

Number of units planned: 2,660,000 mg (first year of contract)

Maximum estimated budget: EUR 2 793 000.00 (first year of contract)